ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

EKF Ekf Diagnostics Holdings Plc

27.60
-0.20 (-0.72%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.20 -0.72% 27.60 27.10 28.90 27.60 27.60 27.60 82,356 09:40:20
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Med, Dental, Hosp Eq-whsl 52.61M 2.35M 0.0052 53.08 125.56M

Renalytix AI PLC Clarification re. lock-up restrictions (5675N)

21/01/2019 7:00am

UK Regulatory


Ekf Diagnostics (LSE:EKF)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Ekf Diagnostics Charts.

TIDMRENX TIDMEKF

RNS Number : 5675N

Renalytix AI PLC

21 January 2019

Renalytix AI plc

("Renalytix" or the "Company")

Clarification re. lock-up restrictions for Distribution Shares

This announcement relates solely to ordinary shares in the Company which were distributed to certain qualifying shareholders owning EKF Diagnostic Holdings plc shares prior to admission (the "Distribution Shares").

Holders of Distribution Shares are reminded that these shares remain subject to a lock-up restriction until 22 April 2019. To avoid settlement issues and potentially having to repurchase such shares in the market, such persons should therefore avoid attempting to sell Distribution Shares until Tuesday, 23 April 2019 or afterwards.

For further information, please contact:

 
Renalytix AI plc                                                                     www.renalytixai.com 
James McCullough, CEO                                                     Via Walbrook PR or Tel: +1 646 
                                                                                                397 3970 
 
N+1 Singer (Nominated Adviser & Broker)                                               Tel: 020 7496 3000 
Aubrey Powell / James White / George Tzimas (Corporate 
 Finance) 
 Tom Salvesen / Mia Gardner (Corporate Broking) 
 
 
 
Walbrook PR Limited                                       Tel: 020 7933 8780 or renalytix@walbrookpr.com 
Paul McManus / Lianne Cawthorne                                           Mob: 07980 541 893 / 07584 391 
                                                                                                     303 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCLLFLRLAIIFIA

(END) Dow Jones Newswires

January 21, 2019 02:00 ET (07:00 GMT)

1 Year Ekf Diagnostics Chart

1 Year Ekf Diagnostics Chart

1 Month Ekf Diagnostics Chart

1 Month Ekf Diagnostics Chart

Your Recent History

Delayed Upgrade Clock